LV009

· The First Affiliated Hospital with Nanjing Medical University

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for LV009, covering 2025-12-31 to 2026-01-09. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors [EARLY_Phase 1]

See pricing